



NEWS RELEASE

## Evolus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

8/29/2022

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the H.C. Wainwright 24th Annual Global Investment Conference.

---

Event: H.C. Wainwright 24th Annual Global Investment Conference  
Date: Monday, September 12, 2022  
Time: Available on-demand starting at 7:00 am ET

An audio webcast of this event will be available on the investor relations section of Evolus' website at [www.evolus.com](http://www.evolus.com). A replay of the webcast will be available for 90 days after the date of the presentation.

### About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Visit us at [www.evolus.com](http://www.evolus.com), and follow us on [LinkedIn](#), [Twitter](#), [Instagram](#) or [Facebook](#).

Jeuveau® is a registered trademark of Evolus, Inc.

Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Investor/Media Contact:

David K. Erickson, Evolus, Inc.

Vice President, Investor Relations

Tel: 949-966-1798

Email: **david.erickson@evolus.com**

Source: Evolus